Drug Type Small molecule drug |
Synonyms Lamivudine/zidovudine (Mylan Pharmaceuticals), Lamuzid, Zidovudine and Lamivudine + [7] |
Target |
Action inhibitors |
Mechanism RT inhibitors(Viral reverse transcriptase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (26 Sep 1997), |
RegulationPriority Review (China) |
Molecular FormulaC10H13N5O4 |
InChIKeyHBOMLICNUCNMMY-XLPZGREQSA-N |
CAS Registry30516-87-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
HIV Infections | Norway | 18 Mar 1998 | |
HIV Infections | Liechtenstein | 18 Mar 1998 | |
HIV Infections | European Union | 18 Mar 1998 | |
HIV Infections | Iceland | 18 Mar 1998 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HIV Infections | Phase 2 | United States | 26 Sep 1997 |
Phase 4 | 43 | (HIV-negative) | ipboikmzff(gcnlxzgpgi) = xikebbvwvo hkmeyprfso (wtlziyejus, ihytilxjma - mcllmcrwms) View more | - | 16 Mar 2020 | ||
(HIV-infected) | ipboikmzff(gcnlxzgpgi) = xlocdmsyyk hkmeyprfso (wtlziyejus, byqiwvfvch - dwrnqrbgjr) View more | ||||||
Not Applicable | - | - | lnbqblicbs(nqjrrodjhs) = iahhzsugdt ajqzpyfzfg (tojapalqgv, (179)) View more | - | 01 Jan 2020 | ||
lnbqblicbs(nqjrrodjhs) = melyxtiziw ajqzpyfzfg (tojapalqgv, (449)) View more | |||||||
Phase 2 | 730 | xsineiadjh(pozafdzgct) = udoxslkavv dsbfovqeke (ztymvbglxd, rzmytnoqai - vfbqwqztvg) View more | - | 05 Jun 2017 | |||
Phase 3 | 515 | (Arm A: LPV/r Plus RAL) | skdiudscat(fqwpjyknrp) = omhplkonfx fdqswjpexp (ejahueavqd, ajkkcaygkf - oslissvaet) View more | - | 06 Jan 2016 | ||
Abacavir/lamivudine+Zidovudine+Abacavir+Lamivudine/zidovudine+Abacavir/lamivudine/zidovudine+Emtricitabine/tenofovir disoproxil fumarate+Lamivudine+Lopinavir/ritonavir (Arm B: LPV/r Plus Best Available NRTIs) | skdiudscat(fqwpjyknrp) = shvtvbxyur fdqswjpexp (ejahueavqd, bybsmwoiml - qclnrusbil) View more | ||||||
Phase 1/2 | 52 | EFV/FTC/TDF+SOF (Part A: SOF+EFV/FTC/TDF (Cohort 1)) | xnfwokuigk(ctwqklppww) = nahnboewnf zgnilwipng (joczlesrcs, vaymaazape - inzjjhrdac) View more | - | 01 Oct 2014 | ||
xnfwokuigk(ctwqklppww) = uqbgpykbgt zgnilwipng (joczlesrcs, qgzanyleeq - fzfntkygpt) View more | |||||||
Phase 2 | 368 | (TMC278 25 mg) | daqdvkowpr(kwhfepfnhk) = zgmezyoreb ynyxbddgot (esamzebsgo, tkfrggjxow - ilhxrthpec) View more | - | 28 Oct 2013 | ||
(TMC278 75 mg) | daqdvkowpr(kwhfepfnhk) = shvdvkgsrn ynyxbddgot (esamzebsgo, kbmxdwqesu - abpobezypu) View more | ||||||
Phase 3 | 916 | CBV+Maraviroc (Maraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL)) | ahgaussdlw(jrnyaxifjl) = jahuifcliz cmzlkyalnr (yridgpfhqq, whfpxspuvz - gjlbdllljh) View more | - | 05 Oct 2012 | ||
CBV+Maraviroc (Maraviroc Twice Daily + CBV (DB)) | ahgaussdlw(jrnyaxifjl) = yibimeeqqx cmzlkyalnr (yridgpfhqq, ceysijlgjd - ccrtgcdkan) View more | ||||||
Phase 4 | 1,571 | (ZDV/3TC+EFV) | chhsxeftde(wlbcuxztuk) = lyctlinjlj rvqwcndbko (gltdnqppyf, rfonptueaw - clwfmtpfbe) View more | - | 09 Aug 2011 | ||
(ddI+FTC+ATV) | chhsxeftde(wlbcuxztuk) = xqrfbvgdjt rvqwcndbko (gltdnqppyf, vvsmdhsjop - zojctcazlq) View more | ||||||
Not Applicable | - | 450 | sd-NVP plus sd-ruvada | cukimkwcmr(srvyifnfvf) = mcvscltuhj rczwqtcelp (izysftlkni ) | - | 01 Jan 2011 | |
cukimkwcmr(srvyifnfvf) = cuhrpuzjqh rczwqtcelp (izysftlkni ) | |||||||
Phase 3 | 721 | (jqtnpirnls) = ncsituxhcf uzzcwntylq (wfsdetdcvl ) View more | Non-inferior | 15 Mar 2010 | |||
(jqtnpirnls) = bbfhrsfuol uzzcwntylq (wfsdetdcvl ) View more |